Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
US7816497B2 · kind B2 · utility
45Cited by
0References
5Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 9, 2005 |
| Grant date | Oct 19, 2010 |
| Priority date | — |
| Expiry date | Feb 26, 2028 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/164
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Activated C3 (C3a) and its receptor (C3aR) and activated C5 (C5a) and its receptor (C5aR) have been shown to induce vascular endothelial growth factor (VEGF) expression in vitro and in vivo. Compositions and methods for inhibiting C3a, C3aR, C5a and C5aR for the treatment and/or prevention of neovascular disease are provided. Also provided are Novel therapeutic targets and diagnostic markers for choroidal neovascularization.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.